Prolastin Patients Kit

*Required Fields

Prolastin Patients Kit

First Name *

Last Name *

Mailing Address *

Mailing Address 2 (Optional) *

City

State *

 

ZIP Code

Email Address

Telephone *

By checking this box, you agree to give permission to use your personal information to receive disease-state and other helpful information from Grifols, and service providers and parties acting on its behalf. You may revoke your permission at any time. To learn how Grifols will use and protect your personal information please review our Privacy Policy.

right-image-tko-patient

footer-callout

Sign up for PROLASTIN-C LIQUID updates

Sign Up

footer-content-image

PROLASTIN-C Liquid trusted by patients with alpha-1 and their doctors icon

PROLASTIN-C LIQUID: The trusted leader for more than 30 years

PROLASTIN-C LIQUID is the #1 prescribed augmentation therapy, trusted by patients with alpha-1 and their doctors for more than 30 years. More than 4 million PROLASTIN-C infusions have been performed around the world.1


footer-separator

 
 
 

isi_

IMPORTANT SAFETY INFORMATION

PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).

Limitations of Use

  • The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials
  • Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
  • PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established

PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.

Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).

Please see full Prescribing Information for PROLASTIN-C LIQUID.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit  http://www.fda.gov/medwatch, or call 1-800-FDA-1088.